GlassScriptPhysician profile
Stephen Jebaraj Pakkianathan
NPI 1124227566
$4,189.59
in general payments reported to CMS, 2019-2025
25 companies · $425 in 2025
The $425 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,139 · 2020: $225 · 2021: $125 · 2022: $372 · 2023: $326 · 2024: $579 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,307 · Education: $23.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,306.57 |
| Education | $23.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,050.63 | 2019-2024 | |
| Applied Medical Resources Corporation | $669.59 | 2019 | |
| Abbvie INC. | $611.95 | 2019-2025 | |
| Astellas Pharma US INC | $408.56 | 2019-2024 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $264.31 | 2021-2025 | Acessa Provu System, Aptima, Thinprep 2000 Processor |
| Daiichi Sankyo INC. | $189.23 | 2019-2025 | Injectafer |
| Exeltis, USA INC. | $166.78 | 2022-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $147.05 | 2019-2025 | |
| Organon LLC | $70.82 | 2022-2025 | Nexplanon |
| Therapeuticsmd, INC. | $65.12 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $60.58 | 2019 | |
| Olympus America INC. | $59.31 | 2021-2022 | |
| Medtronic, INC. | $56.70 | 2025 | Truclear |
| Sage Therapeutics, LLC | $44.17 | 2025 | Zurzuvae |
| Supernus Pharmaceuticals, INC. | $44.17 | 2025 | Qelbree |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $43.70 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $32.51 | 2022 | |
| Coopersurgical, INC. | $31.24 | 2024-2025 | Paragard T 380a |
| Merck Sharp & Dohme LLC | $28.92 | 2019-2022 | |
| Agiliti Surgical, INC. | $27.23 | 2019 | |
| Axonics, INC. | $25.69 | 2022 | |
| Allergan, INC. | $25.35 | 2019-2020 | |
| Myovant Sciences INC. | $23.87 | 2022 | |
| Sumitomo Pharma America, INC. | $23.00 | 2025 | Myfembree |
| Agile Therapeutics, INC. | $19.11 | 2024 | Twirla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Pakkianathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.